Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking... - Abstract - UK PubMed Central

Abstract

The purpose of this study was to explore the possibility of targeted molecular therapy with anti-epidermal growth factor receptor (anti-EGFR) antibody (cetuximab) for the treatment of mucinous ovarian carcinoma. ...............These results suggest the possibility of targeted molecular therapy with cetuximab for mucinous ovarian carcinoma cells lacking a KRAS gene mutation.

Abstract/full free access: The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors

In research/technical:

Conclusions

Cetuximab (Erbitux) and trastuzumab (Herceptin) distribute slowly, but at higher doses achieve a relatively uniform distribution after about 24 hours, most likely due to their long half-lives in the circulation. There remains poor distribution within hypoxic (hypoxia - a deficiency of oxygen reaching the tissues of the body) regions of tumors.

Merck KGaA - EU regulator calls for review of Erbitux (cetuximab) / cancer vaccine Stimuvax (BLP25 liposome vaccine)

Safety concerns: 
1) Erbitux (cetuximab)
2) cancer vaccine Stimuvax (BLP25 liposome vaccine)